John T.-A. Hsu

1.5k total citations
32 papers, 1.1k citations indexed

About

John T.-A. Hsu is a scholar working on Molecular Biology, Oncology and Hepatology. According to data from OpenAlex, John T.-A. Hsu has authored 32 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 8 papers in Oncology and 7 papers in Hepatology. Recurrent topics in John T.-A. Hsu's work include Hepatitis C virus research (7 papers), Lung Cancer Treatments and Mutations (5 papers) and Liver Disease Diagnosis and Treatment (4 papers). John T.-A. Hsu is often cited by papers focused on Hepatitis C virus research (7 papers), Lung Cancer Treatments and Mutations (5 papers) and Liver Disease Diagnosis and Treatment (4 papers). John T.-A. Hsu collaborates with scholars based in Taiwan, India and United States. John T.-A. Hsu's co-authors include Hsing‐Pang Hsieh, Tiao‐Yin Lin, Wen‐Hsing Lin, Shin‐Ru Shih, Chiung‐Tong Chen, Tzu‐Wen Lien, Teng‐Kuang Yeh, Yu-Sheng Chao, Jia-Tsrong Jan and Chang‐Jer Wu and has published in prestigious journals such as PLoS ONE, Cancer Research and Analytical Biochemistry.

In The Last Decade

John T.-A. Hsu

32 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John T.-A. Hsu Taiwan 17 494 202 152 139 110 32 1.1k
Amy Fung United States 9 361 0.7× 214 1.1× 254 1.7× 99 0.7× 128 1.2× 10 920
Abdelhakim Ahmed‐Belkacem France 17 502 1.0× 210 1.0× 145 1.0× 379 2.7× 59 0.5× 31 1.2k
Michel Garneau Canada 21 495 1.0× 289 1.4× 339 2.2× 113 0.8× 55 0.5× 57 1.3k
Juan J. Martínez‐Irujo Spain 20 451 0.9× 138 0.7× 125 0.8× 127 0.9× 70 0.6× 39 966
Xulin Chen China 21 447 0.9× 208 1.0× 277 1.8× 198 1.4× 175 1.6× 56 1.5k
Sarah L. Greig New Zealand 16 329 0.7× 121 0.6× 81 0.5× 230 1.7× 71 0.6× 28 932
Ingrid Choong United States 12 646 1.3× 357 1.8× 160 1.1× 156 1.1× 164 1.5× 20 1.5k
Henri Moereels Belgium 14 441 0.9× 437 2.2× 213 1.4× 82 0.6× 124 1.1× 29 1.2k
David W. A. Beno United States 21 491 1.0× 180 0.9× 294 1.9× 161 1.2× 186 1.7× 54 1.4k
Aslamuzzaman Kazi United States 27 1.0k 2.1× 196 1.0× 138 0.9× 513 3.7× 101 0.9× 45 2.1k

Countries citing papers authored by John T.-A. Hsu

Since Specialization
Citations

This map shows the geographic impact of John T.-A. Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John T.-A. Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John T.-A. Hsu more than expected).

Fields of papers citing papers by John T.-A. Hsu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John T.-A. Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John T.-A. Hsu. The network helps show where John T.-A. Hsu may publish in the future.

Co-authorship network of co-authors of John T.-A. Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of John T.-A. Hsu. A scholar is included among the top collaborators of John T.-A. Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John T.-A. Hsu. John T.-A. Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kiyuna, Tasuku, Yasunori Tome, Kentaro Miyake, et al.. (2019). Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model. Anticancer Research. 39(9). 4775–4779. 16 indexed citations
2.
3.
Tseng, Ching‐Ping, et al.. (2016). Non-small-cell lung cancer cells combat epidermal growth factor receptor tyrosine kinase inhibition through immediate adhesion-related responses. OncoTargets and Therapy. 9. 2961–2961. 6 indexed citations
4.
Chen, Chiung-Tong, John T.-A. Hsu, Wen‐Hsing Lin, et al.. (2015). Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations. European Journal of Medicinal Chemistry. 100. 151–161. 8 indexed citations
5.
Ke, Yi-Yu, Vivek Kumar Singh, Mohane Selvaraj Coumar, et al.. (2015). Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification. Scientific Reports. 5(1). 11702–11702. 64 indexed citations
6.
Hsu, Kai‐Cheng, John T.-A. Hsu, Hui-Chen Hung, et al.. (2015). Anchor-based classification and type-C inhibitors for tyrosine kinases. Scientific Reports. 5(1). 10938–10938. 10 indexed citations
7.
Lin, Wen‐Hsing, Teng‐Kuang Yeh, Weir‐Torn Jiaang, et al.. (2014). Evaluation of the Antitumor Effects of BPR1J-340, a Potent and Selective FLT3 Inhibitor, Alone or in Combination with an HDAC Inhibitor, Vorinostat, in AML Cancer. PLoS ONE. 9(1). e83160–e83160. 19 indexed citations
8.
Chao, Yu‐Sheng, et al.. (2012). EGFR and myosin II inhibitors cooperate to suppress EGFR‐T790M‐mutant NSCLC cells. Molecular Oncology. 6(3). 299–310. 12 indexed citations
9.
Coumar, Mohane Selvaraj, Yen‐Chun Lee, Shengkai Ko, et al.. (2012). Anti‐influenza Drug Discovery: Identification of an Orally Bioavailable Quinoline Derivative through Activity‐ and Property‐Guided Lead Optimization. ChemMedChem. 7(9). 1546–1550. 5 indexed citations
10.
Ke, Yi‐Yu, Chang‐Ying Chu, Yen‐Chun Lee, et al.. (2012). 3D‐QSAR‐Assisted Drug Design: Identification of a Potent Quinazoline‐Based Aurora Kinase Inhibitor. ChemMedChem. 8(1). 136–148. 23 indexed citations
11.
Hsu, John T.-A., Teng‐Kuang Yeh, Shih-Chieh Yen, et al.. (2012). 3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3). Bioorganic & Medicinal Chemistry Letters. 22(14). 4654–4659. 6 indexed citations
12.
Shih, Shin‐Ru, et al.. (2011). Synergistic Inhibition of Enterovirus 71 Replication by Interferon and Rupintrivir. The Journal of Infectious Diseases. 203(12). 1784–1790. 84 indexed citations
13.
Lin, Wen‐Hsing, et al.. (2011). Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells. Biochemical Pharmacology. 81(11). 1263–1270. 49 indexed citations
14.
Hsiao, Che‐Jen, Yunn‐Fang Ho, John T.-A. Hsu, et al.. (2008). Mana-Hox displays anticancer activity against prostate cancer cells through tubulin depolymerization and DNA damage stress. Naunyn-Schmiedeberg s Archives of Pharmacology. 378(6). 599–608. 8 indexed citations
15.
Lin, Chih‐Chien, et al.. (2006). Stable RNA Interference in Spodoptera frugiperda Cells by a DNA Vector-based Method. Biotechnology Letters. 28(4). 271–277. 13 indexed citations
16.
Hsu, John T.-A., et al.. (2006). Antiviral Drug Discovery Targeting to Viral Proteases. Current Pharmaceutical Design. 12(11). 1301–1314. 26 indexed citations
17.
Yao, Hsien‐Tsung, Yi-Wei Chang, Shih-Jung Lan, et al.. (2006). The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sciences. 79(26). 2432–2440. 78 indexed citations
18.
Chang, Ming‐Ling, et al.. (2005). Emergence of mutation clusters in the HCV genome during sequential viral passages in Sip-L expressing cells. Journal of Virological Methods. 129(2). 170–177. 6 indexed citations
19.
Yeh, Chau‐Ting, et al.. (2003). Inhibition of authentic hepatitis C virus replication by sodium stibogluconate. Biochemical and Biophysical Research Communications. 310(2). 537–541. 15 indexed citations
20.
Lee, Jin‐Ching, et al.. (2003). Development of a cell-based assay for monitoring specific hepatitis C virus NS3/4A protease activity in mammalian cells. Analytical Biochemistry. 316(2). 162–170. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Amy Fung Breakdown of academic impact, for papers by Abdelhakim Ahmed‐Belkacem Breakdown of academic impact, for papers by Michel Garneau Breakdown of academic impact, for papers by Juan J. Martínez‐Irujo Breakdown of academic impact, for papers by Xulin Chen Breakdown of academic impact, for papers by Sarah L. Greig Breakdown of academic impact, for papers by Ingrid Choong Breakdown of academic impact, for papers by Henri Moereels Breakdown of academic impact, for papers by David W. A. Beno Breakdown of academic impact, for papers by Aslamuzzaman Kazi
Rankless by CCL
2026